

10/536,766

=> file casreact

FILE 'CASREACT' ENTERED AT 14:55:11 ON 30 OCT 2007

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE CONTENT:1840 - 27 Oct 2007 VOL 147 ISS 19

New CAS Information Use Policies, enter HELP USAGETERMS for details.

```
*****
*
*   CASREACT now has more than 13.8 million reactions   *
*
*****
```

Some CASREACT records are derived from the ZIC/VINITI database (1974-1999) provided by InfoChem, INPI data prior to 1986, and Biotransformations database compiled under the direction of Professor Dr. Klaus Kieslich.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L2 133 SEA FILE=CASREACT SSS FUL L1 (568 REACTIONS)

L3 4 SEA FILE=CASREACT L2 AND (ZIRCONIU? OR HAFIU?)

=> d l3 1-4 ibib abs fcrd

L3 ANSWER 1 OF 4 CASREACT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 147:257772 CASREACT

TITLE: Process for preparation of chiral benzimidazolyl pyridylmethyl sulfoxides from the corresponding sulfides using chiral transition metal complexes and oxidizing agents.

INVENTOR(S): Dubey, Sushil Kumar; Vig, Gaurav; Singh, Anand; Tripathi, Sushil; Paul, Soumendu

PATENT ASSIGNEE(S): Jubilant Organosys Limited, India

SOURCE: PCT Int. Appl., 21pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007088559	A1	20070809	WO 2007-IN35	20070131
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,				

MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:


IN 2006-DE271

20060201

OTHER SOURCE(S):


MARPAT 147:257772

GI




AB Title compds. (I; R1-R4 = H, alkyl, alkoxy, aryl, aryloxy), were prepared by treatment of the corresponding prochiral sulfides with chiral transition metal complexes and oxidizing agents optionally in presence of an organic solvent, wherein the chiral ligands comprise dicyclohexylidene, diacetonide, or benzylidene derivs. of sugars. Thus, vanadium oxytripropoxide and 1,2,4,5-Di-O-cyclohexylidene-D-fructofuranose were stirred together for 10-15 min in PhMe; 5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-1H-benzimidazole and H₂O were added and the mixture was heated at 50-55° for 1 h; the mixture was cooled to 25-30° followed by addition of diisopropylethylamine and cumene hydroperoxide over 1 h followed by stirring for 45 min. and workup to give 5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, sodium salt in 75% enantiomeric excess.

RX(1) OF 1



1. R:945614-29-9,
R:1686-23-3, PhMe
3. Water
4. Cumene hydroperoxide,
EtN(Pr-i)₂



NOTE: alternative preparation shown, stereoselective

CON: STAGE(1) 10 - 15 minutes, room temperature

STAGE(2) room temperature -> 55 deg C

STAGE(3) 1 hour, 50 - 55 deg C; 55 deg C -> 30 deg C

STAGE(4) 1 hour, 25 - 30 deg C; 45 minutes, 25 - 30 deg C

REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 4 CASREACT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 144:390922 CASREACT

TITLE: Stereoselective oxidation processes for the preparation of chiral substituted sulfoxides from the racemic sulfides

INVENTOR(S): Kumar, Neela Praveen; Khanna, Mahavir Singh; Prasad, Mohan; Kumar, Yatendra

PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India

SOURCE: PCT Int. Appl., 23 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006040635	A1	20060420	WO 2005-IB2946	20051004
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM EP 1802584 A1 20070704 EP 2005-790107 20051004 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR IN 2007DN03340 A 20070831 IN 2007-DN3340 20070503 PRIORITY APPLN. INFO.: IN 2004-DE1957 20041011 WO 2005-IB2946 20051004 OTHER SOURCE(S): MARPAT 144:390922 GI				




AB An enantioselective catalytic oxidation process for the preparation of an optically active enantiomer or an enantiomerically enriched form of a substituted pyridinylmethylsulfinylbenzimidazole [I; R1-R4 = H, C1-4 (un)branched alkyl, C1-4 (un)branched alkoxy, aryl, aryloxy], or its pharmaceutically acceptable salts (e.g., esomeprazole potassium), comprises oxidizing a prochiral sulfide (II; e.g., omeprazole sulfide) in

the presence of a chiral transition metal complex [e.g., titanium isopropoxide and L-(+)-diethyl tartrate] and a base (e.g., diisopropylethylamine) in the absence of an organic solvent with an oxidant (e.g., cumene hydroperoxide) followed by an optional salification (e.g., potassium hydroxide).

RX(1) OF 3



1. Ti(OPr-i)₄,
Di-Et L-tartrate
2. Cumene hydroperoxide,
Di-Et L-tartrate,
EtN(Pr-i)₂
3. KOH, MeOH



K

NOTE: optimization study, stereoselective

CON: STAGE(1) room temperature -> 50 deg C; 1.5 hours; 25 - 30 deg C

STAGE(2) 25 - 30 deg C; 3 hours, 25 - 30 deg C

STAGE(3) 25 - 35 deg C; 15 - 16 hours, 25 - 35 deg C

REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 4 CASREACT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 144:51582 CASREACT

TITLE: Process for the preparation of pyridin-2-ylmethylsulfinyl-1H-benzimidazoles via oxidation of the corresponding sulfides in the presence of zirconium or hafnium complexes.

INVENTOR(S): Kohl, Bernhard; Mueller, Bernd; Weingart, Ralf Steffen

PATENT ASSIGNEE(S): Altana Pharma AG, Germany

SOURCE: PCT Int. Appl., 15 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005118569	A1	20051215	WO 2005-EP52471	20050531
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2005250175	A1	20051215	AU 2005-250175	20050531
CA 2568652	A1	20051215	CA 2005-2568652	20050531
EP 1758889	A1	20070307	EP 2005-752651	20050531

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU


CN 1960987	A	20070509	CN 2005-80017526	20050531
US 2007225500	A1	20070927	US 2006-597373	20061122
KR 2007031945	A	20070320	KR 2006-726831	20061220
IN 2006MN01589	A	20070615	IN 2006-MN1589	20061220
NO 2006006003	A	20061222	NO 2006-6003	20061222

PRIORITY APPLN. INFO.:


EP 2004-102467	20040602
WO 2005-EP52471	20050531

AB A process for preparing mixts. of enantiomers of proton pump inhibitors (PPIs) having a sulfinyl structure comprises oxidation of the corresponding sulfides in the presence of a mixture of enantiomers of chiral zirconium or hafnium complexes. Thus, 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylthio]-1H-benzimidazole was heated with DL-tartaric acid bis(N-pyrrolidinamide) and zirconium tetra-n-propoxide in Me iso-Bu ketone at 40° for 1 h followed by addition of diisopropylethylamine and slow addition of cumene hydroperoxide to give 75% 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulfinyl]-1H-benzimidazole.

RX(1) OF 1



1. C:23519-77-9, C:871366-86-8, i-BuCOMe, PrOH
2. Cumene hydroperoxide, EtN(Pr-i)₂
3. Na₂S₂O₃, NaHCO₃, i-BuCOMe, Water



NOTE: optimization study

CON: STAGE(1) 1 hour, 40 deg C; 40 deg C -> room temperature
STAGE(2) room temperature; 5 - 24 hours, room temperature

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 4 CASREACT COPYRIGHT 2007 ACS on STN



ACCESSION NUMBER: 141:54346 CASREACT

TITLE: A process for preparing (S)-pantoprazole via stereoselective oxidation of pyridinylmethylsulfinylbenzimidazole derivative in the presence of L-tartaric acid derivative and chiral zirconium or hafnium catalyst

INVENTOR(S): Kohl, Bernhard; Mueller, Bernd; Weingart, Ralf Steffen
 PATENT ASSIGNEE(S): Altana Pharma Ag, Germany
 SOURCE: PCT Int. Appl., 14 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004052881	A2	20040624	WO 2003-EP13604	20031203
WO 2004052881	A3	20041104		
W: AE, AL, AU, BA, BR, CA, CN, CO, DZ, EC, EG, GE, HR, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, SG, TN, UA, US, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2507889	A1	20040624	CA 2003-2507889	20031203
AU 2003293749	A1	20040630	AU 2003-293749	20031203
EP 1575941	A2	20050921	EP 2003-789113	20031203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016702	A	20051018	BR 2003-16702	20031203
CN 1717402	A	20060104	CN 2003-80104409	20031203
JP 2006514985	T	20060518	JP 2005-502309	20031203
MX 2005PA05761	A	20050816	MX 2005-PA5761	20050530
IN 2005MN00673	A	20051021	IN 2005-MN673	20050627
US 2006167262	A1	20060727	US 2005-536891	20051125
PRIORITY APPLN. INFO.:			EP 2002-27274	20021206
			DE 2003-10340254	20030829
			WO 2003-EP13604	20031203

GI




AB The invention relates to a novel process for preparing (S)-pantoprazole (I) via stereoselective oxidation of pyridinylmethanysulfinylbenzimidazole derivative in the presence of L-tartaric acid derivative and chiral zirconium or hafnium catalyst. For instance, the title compound I, useful as proton pump inhibitor, was prepared from thiobenzimidazole derivative II in the presence of L-tartaric acid amide via Zr(IV) isopropoxide catalyzed oxidation


10/536,766

by cumene hydroperoxide with a yield of 80% (optical purity was >98%, example 3).

RX(1) OF 1



1. C:63126-10-3,
i-BuCOMe
2. C:23519-77-9,
Me2CHOH
3. EtN(Pr-i)2,
Cumene hydroperoxide,
S:98-82-8
4. NaHCO3, Na2S2O3,
Me2CHOH, Water



NOTE: optimization study, optimized on catalyst, stereoselective

CON: STAGE(1) 40 - 45 deg C
STAGE(2) 40 - 45 deg C; 1 hour; 30 deg C
STAGE(3) 20 hours, 30 deg C

=>